SEP 2 1 2004 DU

Typed or printed name

Signature

Elaine C. Stracker

PTO/SB/21 (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwo	ork Reduction Act of 1995, no	persons are required	Patent and Tradem to respond to a collection of information		S. DEPARTMENT OF COMMERCE splays a valid OMB control number.
			Application Number	10/792,0	012
TR	ANSMITT	AL	Filing Date	3/3/2004	l
	FORM		First Named Inventor	Ron L. I	Hale
(to be used fo	r all correspondence after	r initial filing)	Art Unit	Not yet	known
			Examiner Name	To be as	ssigned
Total Number of F	Pages in This Submission		Attorney Docket Number	00038.03	3CON
		ENCLOS	URES (check all that apply)	)	
Amendment  After  Affid  Extension of  Express Abar  Information D  Certified Cop Document(s  Response to Incomplete A	ttached  / Reply  r Final  avits/declaration(s)  Time Request  indonment Request  Disclosure Statement  by of Priority  Missing Parts/	Petition to Provision Power of Change of Change of Change of Cop, Nun  Remarks  Info. Discl. State	o Convert a nal Application Attorney, Revocation of Correspondence  Disclaimer  for Refund  niber of CD(s)  pries, 7 pages each) prences /64	to C Approf A Approf (Approf Approf A	er Allowance communication Group peal Communication to Board Appeals and Interferences peal Communication to Group opeal Notice, Brief, Reply Brief) oprietary Information atus Letter ther Enclosure(s) (please entify below):
	SIGNATUI	RE OF APPLICA	NT, ATTORNEY, OR AGEN	Τ	
Firm or Individual name	ALEXZA MDC, 100 Elaine C. Stracker, P		Circle, Palo Alto, CA 9430 <b>3</b> ephone (650)-687-3905	Cu	stomer Number 37485
Signature	Flein	O La			
Date	SEP. 2	4 2004			

# CERTIFICATE OF TRANSMISSION/MAILING I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the

Date

SEP. 2 4 2004

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Petent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Suate

9-27-04

The

CERTIFICATE OF MAILING

I HEREBY CERTIFY THAT THIS PAPER AND THE DOCUMENTS REFERRED AS BEING ATTACHED OR ENCLOSED HEREWITH ARE BEING DEPOSITED WITH THE UNITED STATES POSTAL OFFICE ON SEP 2 2004 AS EXPRESS MAIL ADDRESSED TO: MAIL STOP AMENDMENT COMMISSIONER FOR PATENTS: POBOX-1450, ALEXANDRIA, VA 22313-1450

Men Stadio

Efaine C. Stracker

PATENT

Attorney's Docket No.: 00038.03CON

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Hale et al.

Serial No.:

10/792,012

Filed:

3/3/2004

Title

DELIVERY OF RIZATRIPTAN OR ZOLMITRIPTAN THROUGH AN

INHALATION ROUTE

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

#### INFORMATION DISCLOSURE STATEMENT

Dear Sir:

In accordance with their continuing duty of disclosure under 37 CFR §§ §1.97, 1.98 and 1.56, Applicants hereby submit for consideration in the above-identified application the enclosed references. The Information Disclosure statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

For the convenience of the Examiner, the references are listed on a PTO Form 1449 (attached) and copies thereof are enclosed. Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines than an extension and/or other relief is required, Applicants petition for any required relief including any extensions of time and authorizes the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 502731**. Please direct all correspondence to the following customer number.

Respectfully submitted,

	SEP.	24	2004	
Date:				

Elaine C. Stracker J.D., Ph.D., Reg. 43,166

Alexza Molecular Delivery Corporation 1001 East Meadow Circle Palo Alto, CA 94303

TEL: (650) 687-3905 FAX: (650) 687-3999

INFORMATION DISSLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

Docket Number: 00038.03 CON Application Number: 10/792,012

Applicant: Hale et al.

Filing Date: 3/3/2004 Group Art Unit: Not yet known

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
	1.	02/02/1971	3,560,607	Hartley et al.			
	2.	05/27/1980	Re. 30,285	Babington			
	3.	01/23/1990	4,895,719	Radhakrishnun et al.			· · · · · · · · · · · · · · · · · · ·
	4.	09/17/1991	5,049,389	Radhakrishnun			
	5.	02/14/1995	5,388,574	Ingebrethsen			······································
	6.	08/13/1996	5,544,646	Lloyd et al.			
	7.	12/09/1997	5,694,919	Rubsamen et al.			
	8.	04/07/1998	5,735,263	Rubsamen et al.			
	9.	04/14/1998	5,738,865	Baichwal et al.			
	10.	06/02/1998	5,758,637	Ivri et al.		. ***	
	11.	06/29/1999	5,915,378	Lloyd et al.			
	12.	08/10/1999	5,934,272	Lloyd et al.			
	13.	09/28/1999	5,957,124	Lloyd et al.			
	14.	10/05/1999	5,960,792	Lloyd et al.			·····
	15.	11/30/1999	5,993,805	Sutton et al.			
	16.	03/28/2000	6,041,777	Faithfull et al.			
	17.	04/18/2000	6,051,566	Bianco			· · · · · · · · · · · · · · · · · · ·
	18.	08/01/2000	6,095,153	Kessler et al.			
	19.	08/15/2000	6,102,036	Slutsky et al.			<del></del>
	20.	06/05/2001	6,241,969	Saidi et al.			
	21.	07/03/2001	6,255,334	Sands			
	22.	01/14/2003	6,506,762	Horvath et al.			
	23.	02/04/2003	6,514,482	Bartus et al.			
	24.	07/15/2003	6,591,839	Meyer et al.			
	25.	09/06/2001	US 2001/0020147	Staniforth et al.			·
	26.	03/28/2002	US 2002/0037828	Wilson et al.			

**EXAMINER:** 

DATE CONSIDERED:

Group Art Unit: Not yet known

#### Form PTO-1449

# INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

Docket Number: 00038.03 CON	Application Number: 10/792,012
Applicant: Hale et al.	

	27.	05/16/2002	US 2002/0058009	Bartus et al.	
	28.	07/04/2002	US 2002/0086852	Cantor	
	29.	08/22/2002	US 2002/0112723	Schuster et al.	
	30.	11/28/2002	US 2002/0176841	Barker et al.	
4	31.	01/02/2003	US 2003/0004142	Prior et al.	
	32.	02/13/2003	US 2003/0032638	Kim et al.	

Filing Date: 3/3/2004

RELATED ALEXZA MOLECULAR DELIVERY CORPORATION PATENT DOCUMENTS

				2 Sala Cold Clairion Tribin DOCOMBIND
	33.	08/04/2003	10/633,876	Hale et al.
	34.	08/04/2003	10/633,877	Hale et al.
	35.	12/30/2003	10/749,537	Rabinowitz et al.
	36.	12/30/2003	. 10/749,539	Rabinowitz et al.
	37.	01/27/2004	. 10/766,149	Rabinowitz et al.
	38.	01/27/2004	10/766,279	Rabinowitz et al.
	39.	01/27/2004	10/766,566	Rabinowitz et al.
	40.	01/27/2004	. 10/766,574	Rabinowitz et al.
	41.	01/27/2004	, 10/766,634	Rabinowitz et al.
-	42.	01/27/2004	. 10/766,647	Rabinowitz et al.
	43.	01/28/2004	, 10/767,115	Rabinowitz et al.
-	44.	01/29/2004	, 10/768,205	Rabinowitz et al.
	45.	01/29/2004	. 10/768,220	Rabinowitz et al.
	46.	01/29/2004	10/768,281	Rabinowitz et al.
	47.	01/29/2004	10/768,293	Rabinowitz et al.
•	48.	01/30/2004	. 10/769,046	Rabinowitz et al.
	49.	01/30/2004	. 10/769,051	Rabinowitz et al.
	50.	01/29/2004	, 10/769,157	Rabinowitz et al.
	51.	01/29/2004	. 10/769,197	Rabinowitz et al.
	52.	02/09/2004	. 10/775,583	Rabinowitz et al.
	53.	02/09/2004	. 10/775,586	Rabinowitz et al.
	54.	03/03/2004	. 10/791,915	Hale et al.

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if citation considered, whether or not the citation conformance and not considered. Include a conv of this form with no	n conforms with MPEP 609. Draw a line through the citation if not in

•

# INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

Docket Number:	00038.03 CON	Application Number: 10/792,012
booker riamber.	00038.03 CON	Application Number: 10/792,01

Applicant: Hale et al.

Filing Date: 3/3/2004 Group Art Unit: Not yet known

	55.	03/03/2004	- 10/792,001.	Rabinowitz et al.			
	56.	03/03/2004	. 10/792,013	Rabinowitz et al.			<u> </u>
	57.	03/03/2004	. 10/792,096	Hale et al.			
	58.	03/03/2004	. 10/792,239	Hale et al.	<del></del>		
	. 59.	03/31/2004	10/813,721	Rabinowitz et al.			
	60.	03/31/2004	. 10/813,722	Rabinowitz et al.			
	61.	03/31/2004	10/814,690	Rabinowitz et al.			
	62.	03/31/2004	. 10/814,998	Rabinowitz et al.			_
	63.	04/01/2004	. 10/815,527	Rabinowitz et al.			
	64.	04/01/2004	10/816,407	Rabinowitz et al.			
	65.	04/01/2004	10/816,492	Rabinowitz et al.			
	66.	04/01/2004	10/816,567	Rabinowitz et al.			
	67.	08/04/2004	10/912,462	Hale et al.			
*	68.	01/23/2003	US 2003/0015196	Hodges et al.		,	· · · · · · · · · · · · · · · · · · ·
1	69.	04/03/2003	US 2003/0062042	Wensley et al.			
	70.	11/13/2003	US 2003/0209240	Hale et al.			
	71.	01/02/2003	US 2003/0000518	Rabinowitz et al.			
	72.	01/09/2003	US 2003/0005924	Rabinowitz et al.			
	73.	01/09/2003	US 2003/0005925	Hale et al.			
	74.	01/09/2003	US 2003/0007933	Rabinowitz et al.			
	75.	01/09/2003	US 2003/0007934	Rabinowitz et al.			
	76.	01/16/2003	US 2003/0012737	Rabinowitz et al.			
	77.	01/16/2003	US 2003/0012738	Rabinowitz et al.		•	
	78.	1/16/2003	US 2003/0012740	Rabinowitz et al.			
	79.	01/23/2003	US 2003/0015189	Rabinowitz et al.			
	80.	01/23/2003	US 2003/0015190	Rabinowitz et al.			
	81.	01/23/2003	US 2003/0017114	Rabinowitz et al.			
	82.	01/23/2003	US 2003/0017115	Rabinowitz et al.			
	83.	01/23/2003	US 2003/0017116	Rabinowitz et al.			
	84.	01/23/2003	US 2003/0017117	Rabinowitz et al.		·····	
*	85.	01/23/2003	US 2003/0017118	Rabinowitz et al.			

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

PTO/SB/ 08 (2-92) pa-729792

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

#### INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

Docket Number:	00038.03 CON	Application Number:	10/792,012

Applicant: Hale et al.

Filing Date: 3/3/2004 Group Art Unit: Not yet known

86.       01/23/2003       US 2003/0017119       Rabinowitz et al.         87.       01/23/2003       US 2003/0017120       Rabinowitz et al.         88.       1/30/2003       US 2003/0021753       Rabinowitz et al.         89.       01/30/2003       US 2003/0021754       Rabinowitz et al.         90.       01/30/2003       US 2003/0021755       Hale et al.         91.       02/20/2003       US 2003/0035776       Hodges et al.         92.       05/15/2003       US 2003/0091511       Rabinowitz et al.         93.       05/27/2004       US 2004/010148       Hale et al.	
88.       1/30/2003       US 2003/0021753       Rabinowitz et al.         89.       01/30/2003       US 2003/0021754       Rabinowitz et al.         90.       01/30/2003       US 2003/0021755       Hale et al.         91.       02/20/2003       US 2003/0035776       Hodges et al.         92.       05/15/2003       US 2003/0091511       Rabinowitz et al.         93.       05/27/2004       US 2004/010148       Hale et al.	
89.       01/30/2003       US 2003/0021754       Rabinowitz et al.         90.       01/30/2003       US 2003/0021755       Hale et al.         91.       02/20/2003       US 2003/0035776       Hodges et al.         92.       05/15/2003       US 2003/0091511       Rabinowitz et al.         93.       05/27/2004       US 2004/010148       Hale et al.	
90.       01/30/2003       US 2003/0021755       Hale et al.         91.       02/20/2003       US 2003/0035776       Hodges et al.         92.       05/15/2003       US 2003/0091511       Rabinowitz et al.         93.       05/27/2004       US 2004/010148       Hale et al.	
91.       02/20/2003       US 2003/0035776       Hodges et al.         92.       05/15/2003       US 2003/0091511       Rabinowitz et al.         93.       05/27/2004       US 2004/010148       Hale et al.	
92.       05/15/2003       US 2003/0091511       Rabinowitz et al.         93.       05/27/2004       US 2004/010148       Hale et al.	
93. 05/27/2004 US 2004/010148 Hale et al.	
94. 07/31/2003 US 2003/0138382 Rabinowitz	•
95. 11/06/2003 US 2003/0206869 Rabinowitz et al.	·
96. 01/15/2004 US 2004/0009128 Rabinowitz et al.	
97. 05/20/2004 US 2004/0096402 Hodges et al.	
98. 05/27/2004 US 2004/0099269 Hale et al.	
99. 06/03/2004 US 2004/0105818 Hale et al.	
100. 06/03/2004 US 2004/0105819 Hale et al.	
101. 07/01/2004 US 2004/0126326 Rabinowitz et al.	
102. 07/01/2004 US 2004/0126327 Rabinowitz et al.	
103. 07/01/2004 US 2004/0126328 Rabinowitz et al.	
104. 07/01/2004 US 2004/0126329 Rabinowitz et al.	
105. 07/01/2004 US 2004/0127481 Rabinowitz et al.	
106. 07/01/2004 US 2004/0127490 Rabinowitz et al.	
107. 08/12/2004 US 2004/0156788 Rabinowitz et al.	
108. 08/12/2004 US 2004/0156789 Rabinowitz et al.	•
109. 8/12/2004 US 2004/0156790 Rabinowitz et al.	
* 110. 08/12/2004 US 2004/0156791 Rabinowitz et al.	

# \* did not received

#### FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO	
EXAMINER:				DATE CONSIDERED:				
EXAMINE conformance	R: Initial	l if citation consider t considered. Includ	ed, whether or not the citation e a copy of this form with nex	conforms with MPEP 609.	Draw a line	through the ci	tation if not in	

# INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

Application Number: 10/792,012

Applicant: Hale et al.

Filing Date: 3/3/2004

Group Art Unit: Not yet known

*	111.	03/14/1990	EP 0 358 114	Europe		
1	112.	07/03/2001	EP 1 080 720	Europe		
	113.	08/29/2001	EP 0 606 486	Europe		
	114.	04/11/1996	WO 96/09846	WIPO		
	115.	05/09/1996	WO 96/13161	WIPO		
	116.	05/09/1996	WO 96/13290	WIPO		
	117.	05/09/1996	WO 96/13291	WIPO		
	118.	05/09/1996	WO 96/13292	WIPO		
	119.	10/03/1996	WO 96/30068	WIPO		
	120.	08/07/1997	WO 97/27804	WIPO		
	121.	01/22/1998	WO 98/02186	WIPO		
	122.	05/28/1998	WO 98/22170	WIPO		٠.
	123.	07/23/1998	WO 98/31346	WIPO		
	124.	08/13/1998	WO 98/34595	WIPO		
	125.	08/27/1998	WO 98/36651	WIPO		
	126.	04/08/1999	WO 99/16419	WIPO		,
	127.	12/16/1999	WO 99/64094	WIPO		
	128.	01/06/2000	WO 00/00176	WIPO		
	129.	01/06/2000	WO 00/00215	WIPO		
	130.	05/18/2000	WO 00/27363	WIPO	,	
	131.	05/25/2000	WO 00/29053	WIPO		
	132.	09/17/2000	WO 00/47203	WIPO		
	133.	11/02/2000	WO 00/64940	WIPO		
	134.	11/09/2000	WO 00/66084	WIPO		
	135.	11/09/2000	WO 00/66206	WIPO		
	136.	12/21/2000	WO 00/76673	WIPO		
	137.	03/01/2001	WO 01/13957	WIPO		
	138.	03/15/2001	WO 01/17568	WIPO		
*	139.	03/28/2002	WO 02/24158	WIPO		

### \* did not received

**EXAMINER:** 

DATE CONSIDERED:

# INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

Sheet 6 of 7	
Application Number: 10/792,012	
Group Art Unit: Not yet known	

#### OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

		(including dution, title, Date, Fertinent Fages, Etc.)			
Examiner Initials	Ref. No.	Title			
	140.	Bennett, R. L. et al. (1981). "Patient-Controlled Analgesia: A New Concept of Postoperative Pain Relief," Annual Surg. 195(6):700-705.			
	141.	Carroll, M.E. et al. (1990), "Cocaine-Base Smoking in Rhesus Monkey: Reinforcing and Physiological Effects," Psychopharmacology (Berl) 102:443-450.			
	142.	Clark, A. and Byron, P. (1986). "Dependence of Pulmonary Absorption Kinetics on Aerosol Particle Size," Z. Erkrank. 166:13-24.			
	143.	Darquenne, C. et al. (1997). "Aerosol Dispersion in Human Lung: Comparison Between Numerical Simulations and Experiments for Bolus Tests," <i>American Physiological Society</i> . 966-974.			
	144.	Davies, C. N. et al. (May 1972). "Breathing of Half-Micron Aerosols," <i>Journal of Applied Physiology</i> . 32(5):591-600.			
	145.	Dershwitz, M., M.D., et al. (September 2000). "Pharmacokinetics and Pharmacodynamics of Inhaled versus Intravenous Morphine in Healthy Volunteers," <i>Anesthesiology</i> . 93(3): 619-628.			
	146.	Finlay, W. H. (2001). "The Mechanics of Inhaled Pharmaceutical Aerosols", Academic Press: San Diego Formula 2.39. pp.3-14 (Table of Contents). pp. v-viii.			
-	147.	Gonda, I. (1991). "Particle Deposition in the Human Respiratory Tract," Chapter 176, The Lung: Scientific Foundations. Crystal R.G. and West, J.B. (eds.), Raven Publishers, New York. pp. 2289-2294.			
-	148.	Hatsukami D., et al. (May 1990) "A Method for Delivery of Precise Doses of Smoked Cocaine-Base to Human." <i>Pharmacology Biochemistry &amp; Behavior</i> . 36(1):1-7.			
	149.	Heyder, J. et al. (1986). "Deposition of Particles in the Human Respiratory Tract in the Size Range 0.005-15 µm," J. Aerosol Sci. 17(5):811-822.			
	150.	Huizer, H. (1987). "Analytical Studies on Illicit Heron. V. Efficacy of Volitization During Heroin Smoking." <i>Pharmaceutisch Weekblad Scientific Edition</i> . 9(4):203-211.			
	151.	Hurt, R. D., MD and Robertson, C. R., PhD, (October 1998). "Prying Open the Door to the Tobacco Industry's Secrets About Nicotine: The Minnesota Tobacco Trial," JAMA 280(13):1173-1181.			
	152.	Lichtman, A. H. et al. (1996). "Inhalation Exposure to Volatilized Opioids Produces Antinociception in Mice," <i>Journal of Pharmacology and Experimental Therapeutics</i> . 279(1):69-76 XP-001118649.			
	153.	Martin, B. R. and Lue, L. P. (May/June 1989). "Pyrolysis and Volatilization of Cocaine," Journal of Analytical Toxicology 13:158-162.			
_*	154.	Mattox, A.J. and Carroll, M.E. (1996). "Smoked Heroin Self-Administration in Rhesus Monkeys," <i>Psychopharmacology</i> 125:195-201.			

**EXAMINER:** 

DATE CONSIDERED:

# INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

Docket Number: 00038.03 CON	Application Number: 10/792,012
Applicant: Hale et al.	
Filing Date: 3/3/2004	Group Art Unit: Not yet known

*	155.	Meng, Y. et al. (1997). "Inhalation Studies with Drugs of Abuse", NIDA Research Monograph 173:201-224.
	156.	Meng, Y., et al. (1999). "Pharmacological effects of methamphetamine and other stimulants via inhalation exposure," <i>Drug and Alcohol Dependence</i> . 53:111-120.
	157.	Office Action mailed 8/13/2003 for US application 10/153,313 filed 05/21/2002 "Delivery of Benzodiazepines Through an Inhalation Route".
	158.	Pankow, J. F. et al. (1997). "Conversion of Nicotine in Tobacco Smoke to Its Volatile and Available Free-Base Form through the Action of Gaseous Ammonia," <i>Environ. Sci. Technol.</i> 31:2428-2433.
	159.	Pankow, J. (March 2000). ACS Conference-San Francisco-3/26/00. Chemistry of Tobacco Smoke. pp. 1-8.
	160.	Seeman, J. et al. (1999). "The Form of Nicotine in Tobacco. Thermal Transfer of Nicotine and Nicotine Acid Salts to Nicotine in the Gas Phase," J. Agric. Food Chem. 47(12):5133-5145.
	161.	Sekine, H. and Nakahara, Y. (1987). "Abuse of Smoking Methamphetamine Mixed with Tobacco: 1. Inhalation Efficiency and Pyrolysis Products of Methamphetamine," <i>Journal of Forensic Science</i> 32(5):1271-1280.
	162.	Vapotronics, Inc. (1998) located at <a href="http://www.vapotronics.com.au/banner.htm">http://www.vapotronics.com.au/banner.htm</a> , 11 pages, (visited on June 5, 2000).
	163.	Ward, M. E. MD, et al. (December 1997). "Morphine Pharmacokinetics after Pulmonary Administration from a Novel Aerosol Delivery System," Clinical Pharmocology & Therapeutics 62(6):596-609.
*	164.	Wood, R.W. et al. (1996). "Generation of Stable Test Atmospheres of Cocaine Base and Its Pyrolyzate, Methylecgonidine, and Demonstration of Their Biological Activity." <i>Pharmacology Biochemistry &amp; Behavior</i> . 55(2):237-248.

\* did not received

EXAMINER:		DATE CONSIDERED:	
		 <u> </u>	